Precipio, Inc. (NASDAQ:PRPO – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.62 and traded as low as $6.61. Precipio shares last traded at $6.74, with a volume of 1,653 shares.
Precipio Stock Performance
The company has a current ratio of 1.17, a quick ratio of 1.05 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average price of $6.40 and a 200 day moving average price of $6.62. The firm has a market cap of $9.63 million, a PE ratio of -1.48 and a beta of 1.61.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Precipio stock. Virtu Financial LLC purchased a new position in shares of Precipio, Inc. (NASDAQ:PRPO – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 45,146 shares of the biotechnology company’s stock, valued at approximately $25,000. Virtu Financial LLC owned 0.20% of Precipio as of its most recent SEC filing. Institutional investors and hedge funds own 10.45% of the company’s stock.
Precipio Company Profile
Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests.
See Also
- Five stocks we like better than Precipio
- How to Invest in Biotech Stocks
- The Charles Schwab Company Can Hit New Highs
- Insider Buying Explained: What Investors Need to Know
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.